ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.

Lung Neoplasms Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00051506
• Other study ID #: 7210
• Secondary ID: H3E-US-JMFW
• Status: Completed
• Phase: Phase 2
• First received: January 10, 2003
• Last updated: July 18, 2006

Study information

• Verified date: July 2006
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effects (good and bad) of ALIMTA plus Carboplatin or ALIMTA plus Cisplatin on you and your small cell lung cancer.

Other known NCT identifiers

• NCT00062088

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have a diagnosis of extensive stage small cell lung cancer and can be treated with chemotherapy.

• Have received no prior chemotherapy for your disease.

• Have at least one measurable lesion.

• have an adequate performance status.

• Sign an informed consent form.

Exclusion Criteria:

• Have previously received chemotherapy for your lung cancer.

• Have been treated with a investigational drug within the last 30 days. Have previously completed or withdrawn from this study or any other study investigating ALIMTA.

• Have received radiation therapy within the last 1-2 weeks.

• Have brain metastasis that is uncontrolled.

• Have active infection or other serious condition.

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lung Neoplasms

Intervention

Drug:
• ALIMTA

• carboplatin

• cisplatin

Locations

Country	Name	City	State
United States	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.	Burlington	North Carolina
United States	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.	Chapel Hill	North Carolina
United States	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.	Charleston	South Carolina
United States	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.	Fort Myers	Florida
United States	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.	Latham	New York
United States	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.	Los Angeles	California
United States	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.	Miami	Florida
United States	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.	Springdale	Arkansas

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

United States,